All‐cause mortality · people with traumatic head injuries
It is very uncertain whether antiepileptic drugs changes all‐cause mortality compared with placebo or standard care (very low certainty).
1 finding from 1 review
Seizures · people with traumatic head injuries
1 finding from 1 review
Early seizures (number of seizures) · people with traumatic head injuries
Neuroprotective agent showed no clear difference in early seizure Count of events compared with placebo (low certainty).
1 finding from 1 review
Late seizures (number of seizures) · people with traumatic head injuries
Neuroprotective agent showed no clear difference in late seizure Count of events compared with placebo (high certainty).
1 finding from 1 review
All‐cause mortality · people with traumatic head injuries
Neuroprotective agent showed no clear difference in all‐cause mortality compared with placebo (high certainty).
1 finding from 1 review
Participant‐reported pain relief of 50% or greater · patients with pain in Guillain‐Barré syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Rescue analgesic consumption · patients with pain in Guillain‐Barré syndrome
It is very uncertain whether carbamazepine changes rescue analgesic consumption compared with placebo (very low certainty).
1 finding from 1 review
Participant‐reported pain relief of 50% or greater · patients with pain in Guillain‐Barré syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of participants with pain after 4 weeks · patients with pain in Guillain‐Barré syndrome
Methylprednisolone showed no clear difference in number of participants with pain after 4 weeks compared with placebo (low certainty).
1 finding from 1 review
Number of participants with decreased pain after 4 weeks · patients with pain in Guillain‐Barré syndrome
Methylprednisolone showed no clear difference in number of participants with decreased pain after 4 weeks compared with placebo (low certainty).
1 finding from 1 review
Number of participants with increased pain after 4 weeks · patients with pain in Guillain‐Barré syndrome
Methylprednisolone showed no clear difference in number of participants with increased pain after 4 weeks compared with placebo (low certainty).
1 finding from 1 review
Participant‐reported pain relief of 50% or greater · intensive care unit in India
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · intensive care unit in India
1 finding from 1 review
no estimate extracted
24 participants
Very low
Sedation score (numerical rating scale of 1 to 6: 0 = anxious, agitated, or restless, 6 = asleep, no response) · intensive care unit in India
1 finding from 1 review
no estimate extracted
24 participants
Very low
Rescue analgesic consumption · intensive care unit in India
It is very uncertain whether gabapentin changes rescue analgesic consumption compared with carbamazepine (very low certainty).
1 finding from 1 review
no estimate extracted
24 participants
Very low
Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · patients with pain in Guillain‐Barré syndrome
It is very uncertain whether gabapentin changes pain score (numerical rating scale of 0 to 10: 0 = no pain, 10 =… compared with placebo (very low certainty).
1 finding from 1 review
Sedation score (numerical rating scale of 1 to 6: 0 = anxious, agitated, or restless, 6 = asleep, no response) · patients with pain in Guillain‐Barré syndrome
It is very uncertain whether gabapentin changes sedation score (numerical rating scale of 1 to 6: 0 = anxious,… compared with placebo (very low certainty).
1 finding from 1 review
Rescue analgesic consumption · patients with pain in Guillain‐Barré syndrome
It is very uncertain whether gabapentin changes rescue analgesic consumption compared with placebo (very low certainty).
1 finding from 1 review
Nausea · patients with pain in Guillain‐Barré syndrome
It is very uncertain whether gabapentin changes nausea compared with placebo (very low certainty).
1 finding from 1 review
Constipation · patients with pain in Guillain‐Barré syndrome
It is very uncertain whether gabapentin changes constipation compared with placebo (very low certainty).
1 finding from 1 review